Additional Prognostic Value of Tumor Grade Beyond the 21-gene Recurrence Score

Prognostic Implication of Tumor Grade in Patients With Node-negative Breast Cancer Aged ≤ 50 Years With 21-gene Recurrence Scores of 11-25

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07093775

Enrollment

4000

Registered

2025-07-30

Start date

2025-07-31

Completion date

2026-03-31

Last updated

2025-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Tumor Grade

Brief summary

To evaluated the prognostic significance of tumor grade in patients with node-negative, hormone receptor-positive, and human epidermal growth factor receptor 2-negative breast cancers treated according to RS-guided strategies.

Interventions

OTHERTumor grade (I or II vs. III)

We compared the prognosis according to the tumor grade stratified by 21-gene recurrence score

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with hormone receptor-positive, HER2-negative early-stage breast cancer * Patients treated between January 2011 and December 2023 * Patients with available clinicopathologic data and 21-gene Oncotype DX assay results confirmed through electronic medical records

Exclusion criteria

* Patients with breast cancer under the age of 20 * Patients diagnosed with stage IV breast cancer * Patients for whom clinicopathologic data cannot be retrieved from electronic medical records

Design outcomes

Primary

Measure	Time frame
Recurrence-free interval	through study completion, an average of 5 year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026